Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Exocrine pancreas

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    56 result(s) found for: Exocrine pancreas. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-000178-21 Sponsor Protocol Number: 0000767 Start Date*: Information not available in EudraCT
    Sponsor Name:Altus Pharmaceuticals Inc.
    Full Title: An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011765 Cystic fibrosis pancreas LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001219-11 Sponsor Protocol Number: PNCRLPCYS3001 Start Date*: 2015-03-31
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
    Full Title: A randomized double-blind (withdrawal) phase 3 study to evaluate the efficacy and tolerability of pancrelipase MT capsules compared with placebo in the treatment of subjects with cystic fibrosis-d...
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10011765 Cystic fibrosis pancreas LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000171-41 Sponsor Protocol Number: 0000726 Start Date*: Information not available in EudraCT
    Sponsor Name:Altus Pharmaceuticals Inc
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insuff...
    Medical condition: Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011766 Cystic fibrosis pancreatic LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) IT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004236-40 Sponsor Protocol Number: I1-GOA-1 Start Date*: 2007-12-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer
    Medical condition: advanced metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002586-36 Sponsor Protocol Number: PACT-9 Start Date*: 2005-07-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.
    Medical condition: PANCREAS TUMOR TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003086-14 Sponsor Protocol Number: EFC6596 Start Date*: 2006-10-09
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Pancreatic Cancer Previousl...
    Medical condition: Advanced Pancreatic Cancer.
    Disease: Version SOC Term Classification Code Term Level
    11.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) DE (Completed) IT (Completed) GB (Completed) HU (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018900-10 Sponsor Protocol Number: FLIP110 Start Date*: 2010-05-11
    Sponsor Name:Laboratoires Mayoly Spindler
    Full Title: Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis
    Medical condition: Exocrine pancreatic insufficiency resulting from chronic pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001852-38 Sponsor Protocol Number: EFC10203 Start Date*: 2007-12-21
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Panc...
    Medical condition: Advanced Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033609 Pancreatic carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000053-30 Sponsor Protocol Number: A4061016 Start Date*: 2005-07-21
    Sponsor Name:Pfizer Inc. - La Jolla laboratories
    Full Title: A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion
    Medical condition: Treatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreas
    Disease: Version SOC Term Classification Code Term Level
    5.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002936-27 Sponsor Protocol Number: IOR 157 01 Start Date*: 2007-12-03
    Sponsor Name:ISTITUTO ONCOLOGICO ROMAGNOLO
    Full Title: A Phase II Dose-Finding Study of weekly pemetrexed in combination with Radiotherapy in locally advanced pancreatic adenocarcinoma
    Medical condition: locally advanced adenocarcinoma of the exocrine pancreas not amenable to surgical resection.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052747 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004309-69 Sponsor Protocol Number: SPaCe-01 Start Date*: 2005-01-13
    Sponsor Name:GISCAD
    Full Title: A randomized phase II study of gemcitabine/cisplatin with or without Cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR-positive pancreatic cancer. SpaCe TRIAL.
    Medical condition: Locally advanced or metastatic EGFR-positive pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10015674 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004063-77 Sponsor Protocol Number: ACCEPT Start Date*: 2013-01-17
    Sponsor Name:Klinikum der Universität München, Anstalt des öffentlichen Rechts
    Full Title: Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
    Medical condition: histologically confirmed diagnosis of metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005168-94 Sponsor Protocol Number: KKS-77-05 Start Date*: 2006-06-20
    Sponsor Name:Philipps-University of Marburg
    Full Title: Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer
    Medical condition: The aim is to evaluate the feasibility of the combined treatment of cetuximab and gemcitabine in patients with R0-resectable pancreatic cancer and to evaluate if the progression free survival can b...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001781-32 Sponsor Protocol Number: MAPS Start Date*: 2007-06-14
    Sponsor Name:GISCAD
    Full Title: A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial
    Medical condition: Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must not have been received a first-line chemotherapy. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001238-41 Sponsor Protocol Number: 2006-001238-41 Start Date*: 2007-01-04
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer.
    Medical condition: Patients with unresectable advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011992-61 Sponsor Protocol Number: EMR200066-003 Start Date*: 2009-10-05
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: Ensayo de fase II, aleatorizado, del inhibidor de MEK AS703026 o placebo en combinación con gemcitabina, en pacientes con cáncer de páncreas metastásico no tratados previamente con quimioterapia.
    Medical condition: Tratamiento de primera línea con AS703026 en combinación con gemcitabina del cáncer metastático de páncreas y /o tratamiento de segunda línea con AS703026 tras progresión con monoterapia de gemcita...
    Disease: Version SOC Term Classification Code Term Level
    9 10033577 Pancreas carcinoma recurrent LLT
    9 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000342-12 Sponsor Protocol Number: VIO16EPI07-01 Start Date*: 2008-03-07
    Sponsor Name:Axcan Pharma Inc.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE SAFETY AND EFFICACY OF VIOKASE® 16 FOR THE CORRECTION OF STEATORRHEA IN PATIENTS WITH EXOCRINE P...
    Medical condition: Correction of steatorrhea (malabsorption of dietary fats) in patients with exocrine pancreatic insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005993-12 Sponsor Protocol Number: S245.4.012 Start Date*: 2009-06-18
    Sponsor Name:Solvay Pharmaceutical GmbH
    Full Title: A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon® 25.000 MMS? in subjects after an attack of acute pancreatitis suffering from pancreatic ex...
    Medical condition: Pancreatic exocrine insufficiency after acute pancreatitis. Insuficiencia pancreática exocrina tras un episodio de pancreatitis aguda.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004854-29 Sponsor Protocol Number: S245.4.008 Start Date*: 2007-09-21
    Sponsor Name:Abbott Products GmbH
    Full Title: One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon® 25000 Minimicrospheres™ in subjects with pancreatic exocrine insufficiency after pancreatic sur...
    Medical condition: Pancreatic Exocrine Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004687-30 Sponsor Protocol Number: MM-398-07-03-01 Start Date*: 2012-03-06
    Sponsor Name:Merrimack Pharmaceuticals Inc.
    Full Title: NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who h...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:16:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA